Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-03-03

Clinical Trial Update: Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is recruiting to evaluate adding the antiemetic aprepitant to a multimodal strategy for preventing postoperative nausea and vomiting in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EMEND (aprepitant)

Snippet

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) | Conditions: Nausea and Vomiting, Postoperative, Prevention | Phase 3 | Status: RECRUITING